

Afsaneh Barzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2409891/publications.pdf>

Version: 2024-02-01

70
papers

4,620
citations

411340

20
h-index

129628

63
g-index

70
all docs

70
docs citations

70
times ranked

10047
citing authors

#	ARTICLE	IF	CITATIONS
1	Impacts of the SARS-CoV-2 Pandemic on Young Adult Colorectal Cancer Survivors. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 229-233.	0.7	9
2	Novel Program Offering Remote, Asynchronous Subspecialist Input in Thoracic Oncology: Early Experience and Insights Gained During the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2022, 18, e537-e550.	1.4	5
3	Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates. <i>Oncologist</i> , 2022, 27, 579-586.	1.9	11
4	Health-related quality of life and time from diagnosis among young adult colorectal cancer survivors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 34-34.	0.8	0
5	Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2021, 21, 285-295.	0.9	3
6	Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. <i>Oncologist</i> , 2021, 26, 610-618.	1.9	5
7	Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021, 11, 12191.	1.6	3
8	Etiology and Outcomes of Hepatocellular Carcinoma in an Ethnically Diverse Population: The Multiethnic Cohort. <i>Cancers</i> , 2021, 13, 3476.	1.7	13
9	Time from Diagnosis and Correlates of Health-Related Quality of Life among Young Adult Colorectal Cancer Survivors. <i>Cancers</i> , 2021, 13, 4045.	1.7	10
10	Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 317-324.	1.0	4
11	MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma Trial in Progress.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS252-TPS252.	0.8	16
12	Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey. <i>Cancers</i> , 2021, 13, 5467.	1.7	3
13	Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 10-16.	0.7	2
14	Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer. <i>Oncologist</i> , 2020, 25, e1879-e1885.	1.9	2
15	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020, 26, 5943-5951.	3.2	55
16	Novel Genomic Differences in Cell-Free Circulating DNA Profiles of Young- Versus Older-Onset Colorectal Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 10, 336-341.	0.7	2
17	Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 428-434.	0.6	6
18	Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. <i>Cancers</i> , 2020, 12, 1742.	1.7	4

#	ARTICLE	IF	CITATIONS
19	Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. <i>Pancreas</i> , 2020, 49, 193-200.	0.5	26
20	Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. <i>European Journal of Cancer</i> , 2020, 130, 219-227.	1.3	24
21	The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2020, 38, e16686-e16686.	0.8	7
22	Primary tumor location and survival in colorectal cancer: A retrospective cohort study. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 405-423.	0.8	11
23	How to optimize cancer therapy when coronavirus hits the fan. <i>American Journal of Managed Care</i> , 2020, 26, SP167.	0.8	1
24	Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000483.	1.1	1
25	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. <i>Cancer</i> , 2019, 125, 3853-3863.	2.0	4
26	Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims. <i>Archives of Osteoporosis</i> , 2019, 14, 83.	1.0	5
27	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1070-1082.	5.1	169
28	Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma. <i>Cancer Control</i> , 2019, 26, 107327481984764.	0.7	8
29	Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2019, 107, 100-114.	1.3	12
30	Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. <i>European Journal of Cancer</i> , 2019, 107, 115-123.	1.3	33
31	Genetic variants in <i>CCL5</i> and <i>CCR5</i> genes and serum VEGF levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. <i>International Journal of Cancer</i> , 2019, 144, 2567-2577.	2.3	8
32	Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 564-564.	0.8	0
33	Outlooks on Epstein-Barr virus associated gastric cancer. <i>Cancer Treatment Reviews</i> , 2018, 66, 15-22.	3.4	149
34	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 621-625.	1.0	44
35	Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies. <i>Seminars in Oncology</i> , 2018, 45, 133-150.	0.8	3
36	Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Handâ€™Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018, 17, e395-e414.	1.0	25

#	ARTICLE	IF	CITATIONS
37	<i>Tertiary Care Multidisciplinary Teams Associated with Improved Survival in Rectal Cancer Patients: A Comparative Study</i> . <i>American Surgeon</i> , 2018, 84, 1645-1649.	0.4	5
38	Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 30.	0.6	2
39	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018, 18, 623-632.	0.9	8
40	Secondary Germline Finding in Liquid Biopsy of a Deceased Patient; Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2018, 8, 259.	1.3	5
41	Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. <i>Clinical Colorectal Cancer</i> , 2018, 17, e751-e761.	1.0	37
42	Circadian clock gene PER1 mutations in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12106-12106.	0.8	2
43	Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3576-3576.	0.8	2
44	Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4098-4098.	0.8	0
45	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017, 23, 3657-3666.	3.2	53
46	Comparative effectiveness of screening strategies for colorectal cancer. <i>Cancer</i> , 2017, 123, 1516-1527.	2.0	41
47	Colorectal cancer statistics, 2017. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 177-193.	157.7	3,300
48	Single nucleotide polymorphisms in the IGF1R pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. <i>International Journal of Cancer</i> , 2017, 141, 383-392.	2.3	10
49	Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 459.e15-459.e24.	0.8	3
50	Stomach Cancer Disparity among Korean Americans by Tumor Characteristics: Comparison with Non-Hispanic Whites, Japanese Americans, South Koreans, and Japanese. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 587-596.	1.1	25
51	Potential role of polymorphisms in the transporter genes ENT1 and MATE1 / OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017, 86, 197-206.	1.3	22
52	Tandem repeat variation near the <i>HIC1</i> (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017, 123, 4506-4514.	2.0	8
53	DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. <i>Cancer</i> , 2017, 123, 3732-3743.	2.0	19
54	SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4016-4016.	0.8	8

#	ARTICLE	IF	CITATIONS
55	Trends in colorectal cancer mortality in hispanics: a SEER analysis. <i>Oncotarget</i> , 2017, 8, 108771-108777.	0.8	20
56	Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3585-3585.	0.8	1
57	Molecular classification of cancers with an uncertain diagnosis as candidates for immunotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23183-e23183.	0.8	0
58	Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. <i>Clinical Colorectal Cancer</i> , 2016, 15, e221-e227.	1.0	9
59	Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. <i>Oncotarget</i> , 2016, 7, 53668-53678.	0.8	26
60	Lost in Translation: The Patient-Physician Relationship in the Molecular Era. <i>Journal of Palliative Medicine</i> , 2015, 18, 987-988.	0.6	0
61	Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2401-2408.	1.9	25
62	Comparative Effectiveness of Screening Strategies for Lynch Syndrome. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	44
63	Immunotherapeutic Strategies for Colon Cancer: Monoclonal Antibody Therapy. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 84-91.	1.0	1
64	We Don't Know What We Don't Know About Adolescent and Young Adult Patients with Familial Adenomatous Polyposis-Related Colorectal Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2015, 4, 105-107.	0.7	0
65	Cost-effectiveness of genomic testing for colorectal cancer: are we there yet?. <i>Oncology</i> , 2015, 29, 183-4; 186.	0.4	0
66	Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1319-1332.	1.4	12
67	Timeliness of Adjuvant Chemotherapy for Stage III Adenocarcinoma of the Colon: A Measure of Quality of Care. <i>Clinical Colorectal Cancer</i> , 2013, 12, 275-279.	1.0	24
68	Molecular Pathways: Estrogen Pathway in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5842-5848.	3.2	181
69	Angiogenesis-related agents in esophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1335-1345.	1.4	11
70	Myelodysplastic syndromes: A practical approach to diagnosis and treatment. <i>Cleveland Clinic Journal of Medicine</i> , 2010, 77, 37-44.	0.6	33